Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

NCT05303961 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: SA001 240mg + Rebamipide 200mg or Placebo
DRUG: SA001 480mg or Placebo
DRUG: SA001 710mg + Rebamipide 600mg or Placebo
DRUG: SA001 1,080mg or Placebo
DRUG: SA001 360mg or Placebo
DRUG: SA001 720mg or Placebo
DRUG: SA001 1,080mg or Placebo

Sponsor

Samjin Pharmaceutical Co., Ltd.